All News

COVID infection mask

COVID Outcomes in Dermatomyositis

d Jack Cush, MD

A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).

Read Article
RheumNow Podcast square

Does Fibromyalgia Need B12? (9.9.2022)

d Jack Cush, MD

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.

Read Article
doctor.MD.IV.complex.treat

ACR Questions Medicare Proposed Cuts to Critical Services Reimbursement by Cognitive Specialists

d ACR

In comments submitted to the Centers for Medicare and Medicaid Services (CMS) in response to the CY 2023 Medicare Physician Fee Schedule and Quality Payment Program proposed rule, the American College of Rheumatology applauded proposals that would provide more flexibility and improve care coordination, while raising concerns about proposed cuts to reimbursement for critical services provided by rheumatologists and other cognitive specialists.

Read Article
SLE,malar,black

Does Dendritic Cell Targeted Therapy Work in SLE?

d Jack Cush, MD

A phase 2 trial using litifilimab, a humanized monoclonal antibody binding to blood dendritic cell antigen 2 (BDCA2), demonstrated clinical efficacy in adults with systemic lupus erythematosus (SLE).

Read Article
IPF.lancet.jpg

Pirfenidone Potential in RA-Related Lung Disease

d MedPage Today

Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial, researchers reported here and in a simultaneous journal publication.

Read Article
Rheumatoid,RA,nodules,damage

Global Trends Informing the Future of Rheumatoid Arthritis

d Jack Cush, MD

Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time. 

Read Article
FDA has approved SPEVIGO® (spesolimab-sbzo) an IV injection - the first-approved treatment option for generalized pustular psoriasis (GPP) FLARES. Spesolimab is an interleukin-36 receptor antagonist. https://t.co/zmuB1tyw9W https://t.co/bJiQB5qJNl

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Fibromyalgia Need B12? Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news. https://t.co/NmAQkuBxg1 https://t.co/W89EImXlvE

Links:

Dr. John Cush RheumNow ( View Tweet)
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO Sponsored by Lilly USA Listen to Drs. Mease and Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and skin concerns. https://t.co/lTfz2kUr51 https://t.co/mPbe9ZqZ8f

Links:

Dr. John Cush RheumNow ( View Tweet)
How to predict IBD in AS/SpA? Study of 82 SpA pts undergoing colonoscopy showed: Rectal bleeding, diarrhea, abdominal pain, high Dz activity and calprotectin levels were suggestive of abnormal ileum inflammation and risk of IBD https://t.co/10PKp7uwmx https://t.co/tnU5tu6Ffp

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi inhibit Vaccine responses some - study of 113 RA fully vaccinated pts assess 6wks post 2nd jab - 51 on JAKi and 62 not on JAKi. Pts not on JAK 77.4% had humoral response; 29% less (54.9%) in thos on JAK inhibitors; even more if on MTX + JAKi https://t.co/NtN4XEa2nE https://t.co/0Msto77iUK

Links:

Dr. John Cush RheumNow ( View Tweet)
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/b9Qa6fL9eM https://t.co/6nRu0iuP1a

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/1aSrRsLkel https://t.co/gmh155ty6w

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of Telemedicine in Rheumatology - 36 reports: 27 observational studies, 7 RCTs , 2 controlled trials - most on general rheum. Most show TM as good as usual / in-person care (Dzactivity, pt satisfaction, costs, & feasibility). TM Works https://t.co/04QW8UiB8j https://t.co/846sqKbnX1

Links:

Dr. John Cush RheumNow ( View Tweet)
STARTER study looked at US in 256 RA pts completed the study & were Rx w/ biologics csDMARDS or combination DMARDs. Pts w/ US grey scal or power doppler tenosynovitis better controlled in combination DMARDs than csDMARDs alone (p:0.025) https://t.co/MXLVoIxzmw https://t.co/8N5aV3vAA0

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 130 patients with ITP (w/ 10 later Dx SLE (30 mos F/U). Risk factors for ITP developing SLE included young age (< 40yrs; OR 6.3), organ bleeding (OR 13.7), and ANA (≥ 1:160; OR 6.6) https://t.co/XSJdio2rR1 https://t.co/oCyFjJnxTX

Links:

Dr. John Cush RheumNow ( View Tweet)
StillsNow Podcast August 2022 - Genetic Testing for Autoinflammatory Diseases Featuring a discussion with Dr. Susan Shenoi from Seattle Childrens Hospital https://t.co/W9e6r83R6B https://t.co/rVvDurZz2g

Links:

Dr. John Cush RheumNow ( View Tweet)
New download! Seven Ways to Diagnose Arthritis - Labs https://t.co/mNkLgTj3DW https://t.co/0UTe7ny5Fo

Links:

Dr. John Cush RheumNow ( View Tweet)
Voclosporin Efficacy and Safety in Lupus Nephritis An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year. https://t.co/LSjmRB2Zr3 https://t.co/z9MoJ0uRzz

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 100 Korean systemic sclerosis pts, shows that while many had SSc finger involvement, fingerprints is SSc pts did not change significantly, but may be inadequate/ difficulr with finger deformity, acroosteolysis or digital ulcers https://t.co/JjTIiaLYZv https://t.co/kcFUobVnvi

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×